FERNANDA COOLEY: Open Payments
NPI 1235656216 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,058 in 181 payments from 11 companies in 2025. Trend: 2023 $3,210 · 2024 $4,243 · 2025 $5,058
Food & beverage: $4,835Education: $223
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 25 | $934 |
| Vanda Pharmaceuticals Inc. | 20 | $832 |
| Alkermes, Inc. | 28 | $619 |
| Axsome Therapeutics, Inc. | 16 | $558 |
| Otsuka America Pharmaceutical, Inc. | 14 | $434 |
| E.R. Squibb & Sons, L.L.C. | 21 | $412 |
| Neurocrine BioSciences, Inc. | 13 | $387 |
| Indivior Inc. | 19 | $376 |
| ABBVIE INC. | 16 | $347 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $93 |
Products named: FANAPT, UZEDY, Auvelity, COBENFY, INGREZZA, SUBLOCADE, REXULTI, VRAYLAR.
Industry payments across OK — which companies pay providers there.
